FABP1 and cancer: Although our initial screening samples (3 cases) and following examination using 62 GBC patients have given rise to our expected results, a larger volume with more GBC cohorts from multiple cancer centers are essential for establishing FABP1 as a prognostic biomarker in GBC patients with direct hepatic invasion.